Fulminant Hepatic Failure Associated with 2′,3′-Dideoxyinosine (ddI)
Authors: Kwan Kew Lai, David L. Gang, John K. Zawacki, Timothy P. Cooley
Journal: Annals of Internal Medicine (1991)

Brief Reports15 August 1991Fulminant Hepatic Failure Associated with 2′,3′-Dideoxyinosine (ddI)Kwan Kew Lai, DMD, MD, David L. Gang, MD, John K. Zawacki, MD, Timothy P. Cooley, MDKwan Kew Lai, DMD, MD, David L. Gang, MD, John K. Zawacki, MD, Timothy P. Cooley, MDAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-115-4-283 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptResults from recently published phase I trials (1-3) of 2′,3′-dideoxyinosine (didanosine, ddI) show promise in the treatment of patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex; ddI is currently being evaluated in phase II-III clinical trials and is widely available in an expanded access program. The major clinical toxicities associated with ddI include peripheral neuropathy and pancreatitis. Deaths have been associated with severe cases of pancreatitis. Laboratory abnormalities include hyperuricemia and elevated levels of hepatic aminotransferases. We report a patient with fulminant hepatic failure associated with the use of ddI.A 36-year-old homosexual man with the Gilbert syndrome,...References1. Yarchoan R, Mitsuya H, Thomas R, Pluda J, Hartman N, and Perno C. In vivo activity against HIV and favorable toxicity profile of 2′,3′-dideoxyinosine. Science. 1989;245:412-5. CrossrefMedlineGoogle Scholar2. Lambert J, Seidlin M, Reichman R, Plank C, Laverty M, and Morse G. 2′,3′-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial. N Engl J Med. 1990;322:1330-40. CrossrefGoogle Scholar3. Cooley T, Kunches L, Saunders C, Perkins C, Kelley S, and McLaren C. Treatment of AIDS and AIDS-related complex with 2′,3′-dideoxyinosine given once daily. Rev Infect Dis. 1990;12:S552-60. CrossrefMedlineGoogle Scholar4. Chaves-Carballo E, Gomez M, and Sharbrough F. Encephalopathy and fatty infiltration of the viscera (Reye-Johnson syndrome): a 17-year experience. Mayo Clin Proc. 1975;50:209-15. MedlineGoogle Scholar5. Peters R, Edmondson H, Mikkelsen W, and Tatter D. Tetracyclineinduced fatty liver in nonpregnant patients. A report of six cases. Am J Surg. 1967;113:622-32. CrossrefMedlineGoogle Scholar6. Powell-Jackson P, Tredger J, and Williams R. Hepatotoxicity to sodium valproate: a review. Gut. 1984;25:673-81. CrossrefMedlineGoogle Scholar7. Sheratt J. Hypoglycin, the famous toxin of the unripe Jamaican ackee fruit. Trends in Pharmacological Sciences. 1986;7:186-91. CrossrefGoogle Scholar8. Geneve J, Hayat-Bonan B, Labbe G, DeGott C, Letteron P, and Freneaux E. Inhibition of mitochondrial beta-oxidation of fatty acids by pirprofen. Role in microvesicular steatosis due to this nonsteroidal anti-inflammatory drug. J Pharmacol Exp Ther. 1987;242:1133-7. MedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: Kwan Kew Lai, DMD, MD; David L. Gang, MD; John K. Zawacki, MD; Timothy P. Cooley, MDFrom the University of Massachusetts Medical Center and the University of Massachusetts Medical School, Worcester, Massachusetts; and Boston City Hospital and Boston University School of Medicine, Boston, Massachusetts. For current author addresses, see end of text. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byHepatic Injury due to Drugs, Dietary and Herbal Supplements, Chemicals and ToxinsTrimetazidine enhances myocardial angiogenesis in pressure overload-induced cardiac hypertrophy mice through directly activating Akt and promoting the binding of HSF1 to VEGF-A promoterSuccessful Treatment of Tenofovir Alafenamide-Induced Lactic Acidosis: A Case ReportA 3D cell printing-fabricated HepG2 liver spheroid model for high-content in situ quantification of drug-induced liver toxicityLiver Fibrosis during Antiretroviral Treatment in HIV-Infected Individuals. Truth or Tale?Insights into the antiviral activity of phospholipases A2 (PLA2s) from snake venomsDecreased All-Cause and Liver-Related Mortality Risk in HIV/Hepatitis B Virus Coinfection Coinciding With the Introduction of Tenofovir-Containing Combination Antiretroviral TherapyMedikamentös-toxischer Leberschaden (DILI)The Role of Liver Biopsy in Drug-Induced Liver InjuryUnanticipated Risk in Clinical Research ∗ ∗The editors have included Dr. Stephen Straus'original unedited contribution, penned for the book's 2002 edition and published with minor modification in the second edition in 2007, to honor his memory. This is a classic and compelling chapter with a story that remains relevant today. References to regulation and guidelines may not be current. The editors have added current references as of the time of publication to the end of the chapter.Drugs and ToxinsThe histopathological evaluation of drug-induced liver injuryHAART toxicity masquerading as a surgical abdomenDrug-Induced Liver InjuryA Review of the Toxicity of HIV MedicationsIn Vitro-In Vivo Correlations in Drug Discovery and Development: Concepts and Applications in ToxicologyUnanticipated Risk in Clinical ResearchHepatic injury due to drugs, herbal compounds, chemicals and toxinsDrug-induced toxicity on mitochondria and lipid metabolism: Mechanistic diversity and deleterious consequences for the liverAcquired Immune DysfunctionDidanosineDrug-induced lipotoxicity: Lipodystrophy associated with HIV-1 infection and antiretroviral treatmentGenetic and Functional Mitochondrial Assessment of HIV-Infected Patients Developing HAART-Related HyperlactatemiaFatal Lactic Acidosis Associated With the Use of Combination Oral Medications to Treat Reactivation of Hepatitis BDrug-Induced Hepatotoxicity or Drug-Induced Liver InjuryPPAR and Liver Injury in HIV-Infected PatientsLiver transplantation in HIV-positive patientsThe significance of mitochondrial toxicity testing in drug developmentUridine supplementation antagonizes zalcitabine-induced microvesicular steatohepatitis in miceUnanticipated Risk in Clinical ResearchSevere Liver Disease Associated With Prolonged Exposure to Antiretroviral DrugsAcquired Immunodeficiency Syndrome in the InfantAcquired Immune DysfunctionTreatment of HCV and HIV coinfectionNatural history and predictors of severity of chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infectionToxicité mitochondriale hépatique associée au traitement par les antirétrovirauxTratamiento de la hiperlactatemia sintomática y de la acidosis láctica en pacientes con infección por el virus de la inmunodeficiencia humana en tratamiento con inhibidores de la transcriptasa inversa análogos de los nucleósidosFanconi syndrome associated with didanosine therapyHyperbilirubinemia in the setting of antiviral therapyHyperlactataemia and lactic acidosis in HIV-infected patients receiving antiretroviral therapyEx Vivo Modeling of the Effects of Mycophenolic Acid on HIV Infection: Considerations for Antiviral TherapyHepatitis viruses and human immunodeficiency virus co-infection: pathogenisis and treatmentA Case of Lactic Acidosis Caused by Stavudine in an AIDS PatientHIV Infection and Hepatic Enzyme Abnormalities: Intricacies of the Pathogenic MechanismsSerum l-lactate and pyruvate in HIV-infected patients with and without presumed NRTI-related adverse events compared to healthy volunteersFrequency, Risk Factors, and Outcome of Hyperlactatemia in HIV-positive Persons: Implications for the Management of Treated PatientsAntiretroviral-associated liver injuryDrug-induced steatohepatitisLactic Acidemia in Infection with Human Immunodeficiency VirusToxic Effects of Nucleoside Reverse Transcriptase Inhibitors on the LiverAcute hepatic failure and lactate acidosis associated with antiretroviral treatment for HIVMetabolic Acidosis and Hepatic Steatosis in Two HIV-Infected Patients on Stavudine (d4T) TreatmentPrevalence, risk factors and outcome of hyperlactataemia in HIV-infected patients*Animal models of anti-HIV drugs exposure during pregnancyHyperlactataemia in HIV-Infected Patients: The Role of NRTI-TreatmentSevere Nucleoside-Associated Lactic Acidosis in Human Immunodeficiency Virus–Infected Patients: Report of 12 Cases and Review of the LiteratureAntiretroviral drug toxicity – a challenge for the hepatologist?Hyperlactatemia and HIV-infected Patients with Nucleoside Analog Reverse-transcriptase Inhibitors Treatment: the Clermont HIV Cohort StudySevere Lactic Acidosis and Multiple Organ Failure in HIV Patients treated with Nucleoside Analogues reverse Transcriptase Inhibitors: a Pilot Study of Treatment with L-CarnitineUnanticipated Risk in Clinical ResearchChapter 2 Clinical Features of the Mitochondrial EncephalomyopathiesHepatitis C and human immune deficiency coinfection at the era of highly active antiretroviral therapySymptomatic Elevations of Lactic Acid and Their Response to Treatment Manipulation in Human Immunodeficiency Virus–Infected Persons: A Case SeriesHyperlactatemia and Antiretroviral Therapy: The Swiss HIV Cohort StudyDirect analysis of mitochondrial toxicity of antiretroviral drugsRisk Factors for Severe Hepatic Injury After Introduction of Highly Active Antiretroviral TherapyRisk Factors for Severe Hepatic Injury After Introduction of Highly Active Antiretroviral TherapyAntiretroviral-Induced Hepatic Steatosis and Lactic Acidosis: Case Report and Review of the LiteratureAIDS in the Intensive Care UnitAntiviral TreatmentsHiperlactatemia sintomática en pacientes con infección por el virus de la inmunodeficiencia humana tratados con análogos de nucleósidosTHE MANAGEMENT OF THE CLINICAL COMPLICATIONS OF ANTIRETROVIRAL THERAPYAdverse effects of antiretroviral therapyDidanosine-induced hepatitisFatal Lactic Acidosis and Hepatic Steatosis Due to Combination Nucleoside Analog Therapy for HIV InfectionFatal Lactic Acidosis and Hepatic Steatosis Due to Combination Nucleoside Analog Therapy for HIV InfectionAcute pancreatitis with severe lactic acidosis in an HIV-infected patient on didanosine therapyLactic acidosis and fulminant hepatic failure in a patient treated with didanosine, nelfinavir and stavudineZidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletionInteractions entre les virus de l'immunodéficience humaine et de l'hépatite CAdverse effects of reverse transcriptase inhibitorsAntiviral activity and toxicity of fialuridine in the woodchuck model of hepatitis B virus infectionGeneral introductionZidovudine-induced fatal lactic acidosis and hepatic failure in patients with acquired immunodeficiency syndromeTHE PANCREAS IN AIDSPrinciples of clinical pharmacology in postexposure prophylaxisThe HIV global pandemic: The development and emerging implicationsL-Carnitine, a Modulator of Immunometabolic Homeostasis in Subjects Infected with the Human Immunodeficiency VirusMicrovesicular steatosis and steatohepatitis: role of mitochondrial dysfunction and lipid peroxidationAGA technical review: Malnutrition and cachexia, chronic diarrhea, and hepatobiliary disease in patients with human immunodeficiency virus infectionGASTROINTESTINAL MANIFESTATIONSClinical toxicity of antiretroviral nucleoside analogsThe Role of Antiretroviral Therapy in the Management of HIV Infection in WomenSafety and tolerability of zalcitabine (ddC) in patients with AIDS or advanced AIDS-related complex in the European expanded access programmeHEPATOTOXICITY OF ANTIVIRAL AGENTSHepatic Failure and Lactic Acidosis Due to Fialuridine (FIAU), an Investigational Nucleoside Analogue for Chronic Hepatitis BDrug-Induced HepatotoxicityInhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity10 Pancreatic lesions in HIV-infected patientsHIV: The surgeon's perspective Part 1. Update of pathogenesis, epidemiology and management and risk of nosocomial transmissionFulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapyHepatotoxityRandomized study of two doses of didanosine in children infected with human immunodeficiency virusZalcitabine and didanosineAntiviral drugsA pilot study of 2′,3′-dideoxyinosine for the treatment of chronic hepatitis BDidanosine, a new antiretroviral drugAdverse EffectsInsights Into HIV Chemotherapy*DidanosineAntiretroviral therapy: reverse transcriptase inhibitionDrug-Induced Microvesicular Steatosis and SteatohepatitisHIV in the ICU 15 August 1991Volume 115, Issue 4Page: 283-284KeywordsAcute liver failureAIDSHospital medicineImmunologyInfectious diseasesPancreatitisPatientsPeripheral neuropathyResearch laboratoriesToxicity ePublished: 1 December 2008 Issue Published: 15 August 1991 PDF downloadLoading ...